Variable | β | SE | t Value | p Value | R2 (%) |
Sex (male vs female) | −1.61 | 0.25 | −6.46 | <0.001 | 7.7 |
Age | 0.02 | 0.01 | 2.14 | 0.03 | 0.91 |
Hypertension ever (yes vs no) | 0.98 | 0.29 | 3.38 | 0.008 | 2.25 |
Cancer ever (yes vs no) | 0.75 | 0.55 | 1.37 | 0.17 | 0.47 |
Arthritis duration | 0.02 | 0.013 | 1.40 | 0.16 | 0.39 |
Psoriasis duration | 0.02 | 0.01 | 2.07 | 0.04 | 0.86 |
No of active joints | 0.11 | 0.013 | 8.50 | <0.001 | 12.7 |
No of swollen joints | 0.09 | 0.03 | 2.86 | 0.004 | 1.62 |
Average grip strength in both hands (mm Hg) | −0.01 | 0.002 | −8.39 | <0.001 | 12.9 |
No of damaged joints | 0.02 | 0.01 | 2.25 | 0.03 | 1.01 |
No of fibromyalgia tender points | 0.24 | 0.02 | 10.7 | <0.001 | 21.2 |
PASI | 0.007 | 0.015 | 0.48 | 0.63 | 0.05 |
Morning stiffness (yes vs no) | 2.01 | 0.25 | 8.01 | <0.001 | 11.6 |
ESR (mm/h) | 0.03 | 0.007 | 3.72 | <0.001 | 3.0 |
Haemoglobin (g/l) | −0.04 | 0.009 | −4.52 | <0.001 | 4.3 |
HAQ | 2.62 | 0.16 | 16.77 | <0.001 | 38.1 |
SF-36 pain | −0.07 | 0.004 | −16.46 | <0.001 | 36.8 |
SF-36 mental health | −0.07 | 0.006 | −13.06 | <0.001 | 27.4 |
NSAID ever (yes vs no) | 1.39 | 0.58 | 2.39 | 0.02 | 1.35 |
DMARD ever (yes vs no) | 0.42 | 0.26 | 1.63 | 0.10 | 0.5 |
Immunosuppressives ever (yes vs no) | 1.50 | 0.25 | 5.97 | <0.001 | 6.7 |
Methotrexate ever (yes vs no) | 1.45 | 0.25 | 5.78 | <0.001 | 6.3 |
Oral steroids ever (yes vs no) | 1.46 | 0.33 | 4.43 | <0.001 | 3.8 |
DMARD, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; FSS, fatigue severity scale; HAQ, health assessment questionnaire; NSAID, non-steroidal anti-inflammatory drugs; PASI, psoriasis area and severity index; SF-36, medical outcome survey short form 36.